The Wall Street Journal recently published an article (read it here) about the struggle of enrolling patients in drug trials for rare diseases – by the very nature of being a rare disease, drug trials recruit from the same – limited – pool of patients, who must meet very particular qualifications.
This is why the NF Registry is so vital: an energized, motivated patient community validates to the drug companies that there are patients living with neurofibromatosis in need of treatment. The Registry helps connect the right patient with the appropriate drug trial; the more patients registered, the larger the pool of applicants from which to draw, which will fuel the drug development pipeline.
Learn more about the NF Registry and sign up here: www.nfregistry.org.
